Cargando…
Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study
OBJECTIVE: To evaluate the safety and efficacy of a humanized anti–interleukin-6 receptor antibody, tocilizumab (TCZ), in patients with neuromyelitis optica (NMO). METHODS: Seven patients with anti–aquaporin-4 antibody (AQP4-Ab)-positive NMO or NMO spectrum disorders were recruited on the basis of t...
Autores principales: | Araki, Manabu, Matsuoka, Takako, Miyamoto, Katsuichi, Kusunoki, Susumu, Okamoto, Tomoko, Murata, Miho, Miyake, Sachiko, Aranami, Toshimasa, Yamamura, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4001188/ https://www.ncbi.nlm.nih.gov/pubmed/24634453 http://dx.doi.org/10.1212/WNL.0000000000000317 |
Ejemplares similares
-
Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab
por: Araki, Manabu, et al.
Publicado: (2012) -
Long-term Effects of IL-6 Receptor Blockade Therapy on Regulatory Lymphocytes and Neutrophils in Neuromyelitis Optica Spectrum Disorder
por: Matsuoka, Takako, et al.
Publicado: (2023) -
Plasmablasts as Migratory IgG-Producing Cells in the Pathogenesis of Neuromyelitis Optica
por: Chihara, Norio, et al.
Publicado: (2013) -
Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder
por: Yamashita, Kazuya, et al.
Publicado: (2018) -
Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders
por: Miyamoto, Katsuichi, et al.
Publicado: (2023)